Medicare AdvantageAugust 27, 2024
BMA expands specialty pharmacy precertification list
Effective for dates of service on or after December 1, 2024, the specialty Medicare Part B drugs listed below will be included in our precertification review process.
Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.
HCPCS or CPT® codes | Medicare Part B drugs |
C9399, J9999 | Anktiva (nogapendekin alfa inbekicept-pmln) |
J3590 | Hercessi (trastuzumab-strf) |
C9399, J9999 | Imdelltra (tarlatamab-dlle) |
Blue Medicare Advantage is the trade name of Group Retiree Health Solutions, Inc., an independent licensee of the Blue Cross Blue Shield Association.
PAIBC-CR-064676-24-CPN64481
To view this article online:
Or scan this QR code with your phone